Bioadhesives in Ophthalmology Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Synthetic Polymer-based Tissue Adhesives, naturally derived Polymer-based Adhesive, Mixed (Synthetic & Natural), By Application (Corneal Repair, Allergic Conjunctivitis, Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Surgery, Others), and Region

Bioadhesives In Ophthalmology Market size was valued at X million in 2023 and poised to grow at CAGR X% from 2024-2030. the bioadhesives in the ophthalmology Market is expected to witness significant growth in the coming years, driven by factors like rising prevalence of ophthalmic disorders, increasing demand for minimally invasive surgeries, and growing adoption of drug delivery systems. The shift towards minimally invasive surgical procedures in ophthalmology is a major driver for the Bioadhesives in Ophthalmology Market. Bioadhesives offer several advantages over traditional sutures for wound closure, including reduced tissue trauma, faster healing, and improved cosmetic outcomes. Bioadhesives can bond tissues without needles, minimizing tissue damage and discomfort for patients. Bioadhesives can promote faster wound healing by creating a more secure closure and potentially reducing the risk of infection. They often leave minimal to no scarring, leading to better cosmetic outcomes compared to sutures. These advantages make bioadhesives a favourable choice for ophthalmic surgeons performing delicate procedures on the eye. Moreover, continuous research and development efforts are leading to the creation of novel bioadhesive materials with improved properties.

These advancements are crucial for expanding the applications of bioadhesives in ophthalmology. Developing bioadhesives with superior biocompatibility is a key focus area. This ensures the material integrates well with the ocular tissues and minimizes the risk of adverse reactions. Also, bioadhesives are being designed to deliver drugs to specific areas of the eye, improving treatment efficacy and reducing systemic side effects. Furthermore, the ability to control the rate at which drugs are released from bioadhesive carriers is another area of development. This allows for sustained and targeted delivery of medication. However, developing and manufacturing bioadhesives specifically for ophthalmic use can be expensive. These materials need to meet stringent biocompatibility and safety standards, requiring rigorous testing and quality control procedures.

Bioadhesives In Ophthalmology Market Key Developments:

• In June 2023, Novartis signed an agreement to divest ‘front of eye’ ophthalmology assets to Bausch + Lomb, a global eye health company, in a transaction valued up to US$ 2.5 billion, including US$ 1.75 billion in upfront cash, plus additional milestone payments. The deal includes Xiidra®, the first approved prescription treatment for the signs and symptoms of dry eye disease, and investigational medicine SAF312 (libvatrep), in development as a first-in-class therapy for chronic ocular surface pain (COSP), as well as the rights for use of the AcuStream delivery device in dry eye indications and OJL332, a second generation TRPV1 antagonist in pre-clinical development.